Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction

Background: Vericiguat, a novel oral soluble guanylate cyclase stimulator, decreased the incidence of cardiovascular death and heart failure hospitalization in the cohort receiving triple therapy for heart failure with reduced ejection fraction. However, efficacy and optimal patient selection in rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Makiko, Imamura, Teruhiko, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342475/
https://www.ncbi.nlm.nih.gov/pubmed/37445431
http://dx.doi.org/10.3390/jcm12134396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342475/
https://www.ncbi.nlm.nih.gov/pubmed/37445431
http://dx.doi.org/10.3390/jcm12134396

Ejemplares similares